Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …

Macrophages have diverse phenotypes and functions due to differences in their origin,
location and pathophysiological context. Although their main role in the liver has been …

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one
of the most global problematic metabolic diseases with rapidly increasing prevalence and …

Macrophage-mediated inflammation is critical in the pathogenesis of non-alcoholic
steatohepatitis (NASH). Here, we describe that, with high-fat, high-sucrose-diet feeding …

Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the
mechanisms underlying the plasma glucose level-lowering effects of metformin (1, 1 …

Nonalcoholic fatty liver disease (NAFLD) and its inflammatory and often progressive subtype
nonalcoholic steatohepatitis (NASH) are becoming the leading cause of liver-related …

Obesity is the most common cause of insulin resistance, and the current obesity epidemic is
driving a parallel rise in the incidence of T2DM. It is now widely recognized that chronic …

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases
characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected …

Autophagic pathways cross with lipid homeostasis and thus provide energy and essential
building blocks that are indispensable for liver functions. Energy deficiencies are …